Genetic Analysis of Male Pattern Baldness and the 5α-Reductase Genes  by Ellis, Justine A. et al.
Genetic Analysis of Male Pattern Baldness and the 5a-Reductase
Genes
Justine A. Ellis, Margaret Stebbing, and Stephen B. Harrap
Department of Physiology, The University of Melbourne, Parkville, Victoria, Australia
Genetic predisposition and androgen dependence are
important characteristics of the common patterned loss
of scalp hair known as male pattern baldness. The involve-
ment of the 5a-reductase enzyme in male pattern baldness
has been postulated due to its role in the metabolism of
testosterone to dihydrotestosterone. There are two known
isozymes of 5a-reductase. Type I has been predominantly
localized to the skin and scalp. Type II, also present on
the scalp, is the target of finasteride, a promising treat-
ment for male pattern baldness. We conducted genetic
association studies of the 5a-reductase enzyme genes
(SRD5A1 on chromosome 5 and SRD5A2 on chromo-
some 2) using dimorphic intragenic restriction fragment
length polymorphisms. From a population survey of
828 healthy families comprising 3000 individuals, we
Androgenetic alopecia is characterized by a loss of hairfrom the scalp that follows a defined pattern (Hamilton,1951). It is caused by a shortening of the anagen (growth)phase and miniaturization of the hair follicle, whichresults in the formation of progressively thinner, shorter
hair (Bergfeld, 1995). In men, the condition is often referred to as
male pattern baldness (MPB) and appears to be androgen dependent
(Hamilton, 1942). The disorder is hereditary, and follows a pattern
that may be consistent with an autosomal dominant trait (Osborn, 1916).
Two major androgens determining the male sex phenotype are
testosterone and dihydrotestosterone (DHT). DHT is formed from
testosterone in the cell cytoplasm by the action of the 5α-reductase
enzyme. Both testosterone and DHT appear to bind to the same
androgen receptor in the cell nucleus (Brown et al, 1989), exposing
DNA binding sites, and thereby regulating transcription of androgen-
dependent genes (Randall, 1994).
The androgen-dependent nature of scalp hair loss is demonstrated
by the lack of frontal recession in androgen-insensitive individuals
(those who lack the androgen receptor) (Griffin and Wilson, 1989).
Similarly, no baldness is seen in pseudohermaphrodites who lack an
active 5α-reductase enzyme (Imperato-McGinley et al, 1974). This
suggests that DHT is the more relevant androgen, and implicates the
5α-reductase enzyme in androgenetic alopecia.
Two types of 5α-reductase have been isolated, each encoded by a
separate gene. Biochemically, 5α-reductase types I and II can be
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identified 58 young bald men (aged 18–30 y) and 114
older nonbald men (aged 50–70 y) for a case control
comparison. No significant differences were found
between cases and controls in allele, genotype, or haplo-
type frequencies for restriction fragment length poly-
morphisms of either gene. These findings suggest that
the genes encoding the two 5a-reductase isoenzymes are
not associated with male pattern baldness. Finally, no
clear inheritance pattern of male pattern baldness was
observed. The relatively strong concordance for baldness
between fathers and sons in this study was not consistent
with a simple Mendelian autosomal dominant inherit-
ance. A polygenic etiology should be considered. Key
words: androgenetic alopecia/dihydrotestosterone/finasteride/
hair. J Invest Dermatol 110:849–853, 1998
distinguished by their differing pH optima and sensitivity to the 4-
azasteroid inhibitor finasteride (17β-N-t-butyl-carbamoyl-4-aza-5α-
androst-1-en-3-one). Type I is active over a broad pH range (pH 6.0–
8.5) and is poorly inhibited by finasteride in vitro. Type II is active
over a narrow pH range (around pH 5.0) and is strongly inhibited by
finasteride (Harris et al, 1992; Jenkins et al, 1992).
In an animal model of MPB, the stumptail macaque, finasteride, has
been shown to halt balding and increase hair weight (Diani et al, 1992).
Use of finasteride in men has demonstrated a decrease of DHT in bald
scalp (Dallob et al, 1994) and a reversal of MPB in some men (Marks,
1997). Given the strong inhibition of 5α-reductase type II by finasteride
in vitro, the involvement of this isoenzyme in MPB seems plausible;
however, studies of the tissue distribution of the enzymes have shown
that, whilst type II is present, type I is the predominant 5α-reductase
found in scalp from birth to 3 y, and from puberty throughout adult
life (Thigpen et al, 1993).
The gene encoding the type I enzyme, SRD5A1, is located on
chromosome 5 at 5p15.5 (Jenkins et al, 1991), whilst the gene encoding
the type II enzyme, SRD5A2, is located on chromosome 2 at 2p23
(Thigpen et al, 1993). We have investigated the possibility that mutations
in or very near SRD5A1 and SRD5A2 are determinants of MPB.
Individual variation in these genes can be detected using restriction
fragment length polymorphisms (RFLPs) that have been reported
previously (Jenkins et al, 1991; Morisette et al, 1996). These mutations
that determine the RFLPs do not alter the amino acid sequence
significantly per se, but they can be used as genetic markers of
population variants of these genes. We used a case-control design in
which we compared the frequency of alleles, genotypes, and haplotypes
of the SRD5A1 gene, and alleles and genotypes of the SRD5A2 gene,
in young balding men and older men with no indication of baldness.
MATERIALS AND METHODS
Sampling Approximately 3000 individuals were recruited as part of the
Victorian Family Heart Study. This is a general population survey of coronary
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Table I. Distribution of baldness scores in sons and fathers
surveyed
Sons Fathers
Hamilton scorea n % n %
I 367 69.4 114 21.0
II 104 19.7 88 16.2
III 27 5.1 39 7.2
III vertex 17 3.2 75 13.8
IV 9 1.7 78 14.3
V 3 0.6 62 11.4
VI 0 0 55 10.1
VII 2 0.4 33 6.1
529 100.0 544 100.0
aA baldness score of type I indicates no baldness. A type II score indicates some frontal
recession, but the baldness is not cosmetically significant. Scores of type III and above
indicate cosmetically significant baldness. Type III vertex is a subset of type III where
frontal recession is no more than in type III but significant loss of hair has also occurred
at the vertex (Norwood, 1975).
risk factors and consists of µ800 families, comprising a mother, a father, and at
least one natural offspring. Baldness survey questionnaires were sent to all males
(approximately one half of the sample number) asking them to detail their
degree of baldness, if any, in terms of the Hamilton baldness scale (Hamilton,
1951; Norwood, 1975). The survey described all categories of the scale, and
provided diagrams to assist in the self-assessment. The participant self-assessment
of baldness score was assessed against that determined by an independent,
trained observer in our research clinic. In nine subjects with a self-assessed
score of I, the observer concurred in all but one individual who was given a
score of II (p 5 0.317, Wilcoxon matched pairs signed rank test). In five
subjects with self-assessed scores ranging from III to VII, no discrepancies with
the observer’s score were detected.
A total of 1220 men returned the completed baldness questionnaires. This
group contained 529 sons aged 18–30 y and 544 fathers aged 50 y and above.
Cosmetically significant baldness of type III or greater (Norwood, 1975) was
reported by 58 sons (11.0% of men in this age group) aged 18–30 y (Table I).
These individuals were defined as cases and DNA was available for analysis in
56 of these subjects. A total of 114 fathers aged 50 and above (21.0% of men
in this age range) reported no baldness (Hamilton baldness score of I) and DNA
was available from 108 individuals who comprised the control group for our
genetic analyses.
Analysis of RFLPs of the SRD5A1 gene DNA was extracted from white
blood cells using standard phenol/chloroform techniques. Approximately 50 ng
of DNA from each individual was used in polymerase chain reactions (PCR).
The HinfI RFLP of the SRD5A1 gene was detected by amplification of a
210 bp fragment of exon 1 using primers h5a35 (59-CAGGATCCGAGGCCT-
CTGGCATGGGGAGCACGCTGCC-39) and h5a36 (59-CGAAGCTTCAG-
GCACTCGGAGCCTGTGGCTGGGCA-39) (Jenkins et al, 1991). DNA was
added to a mix containing 0.5 µM of each primer, 1X PCR buffer (Perkin-
Elmer, Norwalk, CT), 250 µM dNTP (Perkin-Elmer), 1.5 mM MgCl2 (Perkin-
Elmer), and 1 unit Amplitaq Gold DNA polymerase (Perkin-Elmer), to give a
total reaction volume of 20 µl. Thermal conditions required for the reaction
were 95°C for 10 min (for activation of the Amplitaq Gold enzyme), followed
by 35 cycles of 95°C for 1 min, 63°C for 1 min, and 72°C for 1 min, followed
by a final extension time of 72°C for 10 min. Products were then digested by
the addition of 5 units of HinfI restriction endonuclease (Boehringer Mannheim,
Indianapolis, IN) in the presence of 1X buffer ‘‘H’’ (Boehringer Mannheim) at
37°C for 1 h. Digested products were then electrophoresed through a 2%
agarose gel (Type II-A, Sigma, St. Louis, MO) containing ethidium bromide.
DNA was visualized by placing the gel on a UV transilluminator.
The NspI RFLP of the SRD5A1 gene was detected in a similar manner.
Primers h5a14 (59-CCCAAATCATTTAAGATAGGATTAC-39) and h5a8
(59-ATGATGTGAACAAGGCGGAGTTCAC-39) were used to amplify a
288 bp fragment of exon 2 of the SRD5A1 gene (Jenkins et al, 1991). Again,
µ50 ng of DNA was added to a reaction mixture as described above. Thermal
conditions required for the reaction were 95°C for 10 min, followed by 35
cycles of 95°C for 1 min, 55°C for 30 s, and 72°C for 2 min, followed by a
final extension of 72°C for 10 min (modified from Jenkins et al, 1991). PCR
products were digested with 5 units of NspI (Boehringer Mannheim) in the
presence of 1X buffer ‘‘M’’ (Boehringer Mannheim) at 37°C for 1 h. Digested
products were electrophoresed and visualized as above.
Analysis of RFLP of the SRD5A2 gene The RsaI RFLP of the SRD5A2
gene was detected by amplification of a 349 bp fragment of exon 1 using
Figure 1. DNA fragment sizes detected with HinfI and NspI RFLPs of
the 5a-reductase type I gene. (a) Fragment sizes for the HinfI RFLP. The
uncut (‘‘A’’) allele is indicated by a fragment of µ210 bp, while the cut (‘‘B’’)
allele is indicated by two fragments of 138 bp and 72 bp. Lane 1, heterozygote
for the ‘‘A’’ and ‘‘B’’ alleles; lane 2, homozygote for the ‘‘A’’ allele; lane 3,
homozygote for the ‘‘B’’ allele. (b) Fragment sizes for the NspI RFLP. The
uncut (‘‘a’’) allele is indicated by a fragment of µ288 bp, while the cut (‘‘b’’)
allele is indicated by two fragments of 151 bp and 137 bp. Lane 1, homozygote
for the ‘‘b’’ allele; lane 2, heterozygote for the ‘‘a’’ and ‘‘b’’ alleles; lane 3,
heterozygote for the ‘‘a’’ and ‘‘b’’ alleles; lane 4, homozygote for the ‘‘a’’ allele.
Figure 2. DNA fragment sizes detected with the RsaI RFLP of the 5a-
reductase type II gene. The allele lacking the polymorphic restriction site,
termed allele ‘‘A,’’ is indicated by two fragments of 256 bp and 93 bp. The
allele containing the polymorphic restriction site, termed allele ‘‘B,’’ is indicated
by three fragments of 236 bp, 93 bp, and 20 bp (the 20 bp fragment could not
be clearly resolved). Lane 1, homozygote for the ‘‘A’’ allele; lane 2, heterozygote
for the ‘‘A’’ and ‘‘B’’ alleles; lane 3, homozygote for the ‘‘B’’ allele.
forward primer 59-CGCCTGGTTCCTGCAGGAGCT-39 and reverse primer
59-GTGAAGGCGGCGTCTGTG-39 (Morisette et al, 1996). Fifty nanograms
DNA was added to a mix containing 0.5 µM of each primer, 1X PCR buffer
(Perkin-Elmer), 250 µM dNTP (Perkin-Elmer), 1.5 mM MgCl2 (Perkin-
Elmer), and 1 unit Amplitaq Gold DNA polymerase (Perkin-Elmer), to give a
total reaction volume of 20 µl. Thermal conditions required for the reaction
were 95°C for 10 min (for activation of the Amplitaq Gold enzyme), followed
by 35 cycles of 95°C for 1 min, 60°C for 1 min, and 72°C for 30 s, followed
by a final extension time of 72°C for 10 min (Morisette et al, 1996). Products
were then digested by the addition of 5 units of RsaI (Boehringer Mannheim)
in the presence of 1X buffer ‘‘L’’ (Boehringer Mannheim) at 37°C for 1 h.
Digested products were electrophoresed and visualized as above.
RESULTS
Demonstration of RFLPs of the SRD5A1 gene Allele sizes of
the SRD5A1 RFLP observed after digestion with HinfI and NspI are
shown in Fig 1. The polymorphisms were defined by the presence or
absence of the specific restriction enzyme cut site. As previously
reported (Jenkins et al, 1991), digestion of the 210 bp fragment from
exon 1 by HinfI resulted in two fragments of 138 bp and 72 bp in the
presence of the cut site (Fig 1a). Digestion of the 288 bp fragment of
exon 2 by NspI resulted in two fragments of 151 bp and 137 bp in
the presence of the cut site (Fig 1b). The uncut (larger) allele for the
HinfI RFLP was designated ‘‘A’’ and the cut (smaller) allele was
designated ‘‘B.’’ For the NspI RFLP the two alleles were designated
‘‘a’’ and ‘‘b’’ for the uncut and cut alleles, respectively.
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Table II. Basal data for cases and controls used in this study
n Age (y)a Weight (kg)a Height (cm)a Body mass index a Baldness scoreb
Cases 56 26 6 0.4 80 6 1.3 177 6 1.1 25.5 6 0.38 III vertex
Controls 108 55 6 0.4 82 6 1.3 174 6 0.7 26.9 6 0.33 I
Fathers of cases 54 57 6 0.8 84 6 1.4 174 6 0.9 27.6 6 0.40 IV
Sons of controls 65 25 6 0.4 78 6 1.6 179 6 0.8 24.3 6 0.50 I
aValues given as mean 6 SEM.
bMedian values given.
Table III. Distribution of SRD5A1 RFLP in young bald men
(cases) and older nonbald men (controls)
HinfI RFLP alleles (%)a NspI RFLP alleles (%)a
A B a b
Cases 49.1 50.9 70.9 29.1
Controls 48.6 51.4 65.4 34.6
aA and a represent the cut alleles, B and b represent the uncut alleles.
Table IV. Distribution of genotypes for each SRD5A1 RFLP
in young bald men (cases) and older nonbald men (controls)
HinfI RFLP genotypes (%)a NspI RFLP genotypes (%)a
AA AB BB aa ab bb
Cases 25.5 47.3 27.2 52.7 36.4 10.9
Controls 22.4 52.4 25.2 41.1 48.6 10.3
aA and a represent the cut alleles, B and b represent the uncut alleles.
Demonstration of RFLP of the SRD5A2 gene Digestion of the
349 bp SRD5A2 PCR product with RsaI demonstrated a biallelic
polymorphism as previously reported (Morisette et al, 1996). Allele
sizes are shown in Fig 2. In the absence of the polymorphic restriction
site, the PCR product was cleaved into two fragments of 256 bp and
93 bp, due to the existence of an additional, nonpolymorphic RsaI
site in the region. This allele was designated the ‘‘A’’ allele. In the
presence of the polymorphic restriction site, the PCR product was
cleaved into three fragments of 236 bp, 93 bp, and 20 bp. This allele
was designated the ‘‘B’’ allele.
Basal data and baldness levels in cases and controls Table II
indicates the mean age, weight, height and body mass index, and
median Hamilton Baldness score of cases and controls used in this
study. Because family data were available it was possible to assess
concordance for MPB between fathers and sons. Data were available
from 54 fathers (96.4%) of the bald sons that were cases in this analysis.
Of these cases, 22 fathers reported no baldness or baldness of an equal
or lesser degree than their sons. The remaining 32 cases had fathers
who reported a greater degree of baldness. Of the controls, 50 had
one or more sons involved in this study (total 65). Only one of these
sons reported a hair distribution of type III baldness or greater. The
basic characteristics of fathers of cases and sons of controls are shown
in Table II.
Lack of association of the SRD5A1 RFLPs with baldness The
ascertainment of SRD5A1 RFLPs was successful in 55 cases and 107
controls. Table III summarizes the distribution of the resulting alleles
after digestion by HinfI and NspI. No significant differences were
found between cases and controls for either allele of each RFLP (HinfI:
χ2 5 0.009, d.f. 5 1, p 5 0.925; NspI: χ2 5 1.003, d.f. 5 1, p 5
0.317). The possible individual genotypes for each RFLP (i.e., AA,
AB, or BB, and aa, ab, or bb) were also compared in cases and controls.
The distribution of genotypes is shown in Table IV. Again no
significant differences in genotypes were detected between groups
(HinfI: χ2 5 0.373, d.f. 5 2, p 5 0.830; NspI: χ2 5 2.288, d.f. 5 2,
p 5 0.319). Finally, it was possible to determine the haplotypes defined
by combinations of alleles from both the HinfI and the NspI RFLP
Table V. Distribution of the SRD5A2 RFLP in young bald
men (cases) and older nonbald men (controls)
Alleles (%)a Genotypes (%)a
A B AA AB BB
Cases 30.4 69.6 7.2 46.4 46.4
Controls 29.0 71.0 6.5 44.9 48.6
aA represents the cut allele, B represents the uncut allele.
(i.e., AA-aa, AA-ab, AA-bb, AB-aa, AB-ab, AB-bb, BB-aa, BB-ab,
or BB-bb). No significant differences in haplotype distributions were
demonstrated between cases and controls (χ2 5 5.950, d.f. 5 8, p 5
0.653) (data not shown).
Given that familial aggregation of baldness may be relevant to the
genetic analysis, we undertook an analysis of cases who had fathers
showing a greater degree of baldness. Compared with controls, this
group showed no significant difference in allele (HinfI: χ2 5 0.481,
d.f. 5 1, p 5 0.488; NspI: χ2 5 2.380, d.f. 5 1, p 5 0.123), genotype
(HinfI: χ2 5 0.609, d.f. 5 2, p 5 0.738; NspI: χ2 5 2.849, d.f. 5 2,
p 5 0.241), or haplotype (χ2 5 9.729, d.f. 5 8, p 5 0.285) frequencies
of the SRD5A1 HinfI and NspI RFLP (data not shown).
Lack of association of the SRD5A2 RFLP with baldness Fifty-
six cases and 107 controls were scored for the ‘‘A’’ and ‘‘B’’ alleles of
the SRD5A2 RsaI RFLP. The distributions of alleles shown in Table V
reveal no significant differences between cases and controls (χ2 5
0.065, d.f. 5 1, p 5 0.798). Similarly, possible genotypes (AA, AB,
BB) were compared between cases and controls (Table V), and no
significant differences were observed (χ2 5 0.074, d.f. 5 2, p 5 0.964).
No significant differences in allele (χ2 5 0.350, d.f. 5 1, p 5 0.554)
or genotype (χ2 5 0.442, d.f. 5 2, p 5 0.810) frequencies were
demonstrated between controls and the subgroup of cases whose fathers
were more bald (data not shown).
Lack of association of SRD5A1 and SRD5A2 RFLP haplotypes
with baldness The 27 possible haplotypes resulting from the com-
bination of alleles of the SRD5A1 HinfI and NspI, and the SRD5A2
RsaI RFLP were compared in cases and controls. No significant
differences in haplotype distributions were detected (χ2 5 19.081,
d.f. 5 26, p 5 0.833) (data not shown).
DISCUSSION
This study has examined the possibility of an association between MPB
and the 5α-reductase type I and 5α-reductase type II enzyme genes.
These enzymes are of particular interest because MPB is associated
with high levels of DHT in the scalp produced from conversion of
testosterone by the 5α-reductase isoenzymes. We used population
variants of the SRD5A1 and SRD5A2 genes that encode the isozymes
of 5α-reductase. Increased levels of both enzymes have been demon-
strated in frontal compared with occipital hair follicles in male and
female androgenetic alopecia (Sawaya and Price, 1997). Our hypothesis
was that these variants would be in close proximity to etiologic genetic
mutations and would therefore be significantly associated with MPB.
To maximize genetic predisposition we compared young men with
premature MPB with older men without MPB selected from the
general population. We were unable to detect any significant difference
in the distribution of SRD5A1 or SRD5A2 markers between bald
852 ELLIS ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
cases and nonbald controls. These data suggest that the known variants
of the SRD5A1 and SRD5A2 genes are not associated with MPB.
It is possible that not all cases of MPB have a genetic explanation.
Therefore, we subgrouped young bald men into those with and those
without an affected relative. Because the degree of baldness increases
with age, we defined fathers as sharing the same affected phenotype if
they were more bald than their sons. The allele, genotype, and
haplotype frequencies of the SRD5A1 RFLPs and the allele and
genotype frequencies of the SRD5A2 RFLP were no different in bald
sons of bald fathers than in nonbald controls; however, the relatively
small number of individuals within this subgroup limits the statistical
power of this particular analysis.
Genetic association studies such as ours assume that RFLP markers
and disease mutations will be tightly linked in the population. As a
result, certain markers would be associated with MPB and one would
expect a significant difference in marker allele frequencies between
cases and controls (Cox and Bell, 1989). In an evolutionary context,
if a mutation had occurred within the SRD5A1 or SRD5A2 genes
contributing to MPB, it would have occurred next to either the A or
the B allele of their corresponding RFLP. As the mutation spread
throughout the population, the close proximity of the mutation and
RFLP should have ensured their coinheritance through the generations.
Therefore, one would expect that in the balding population, a higher
proportion of one RFLP allele would be evident. Our study has failed
to show such a bias.
There are, however, several caveats regarding genetic association
studies. Even if a marker RFLP is in very close proximity to the
disease mutation, other factors may obscure an association. If the
mutation causing the RFLP occurred many generations after that
which is causing the disease, then only some disease-affected individuals
will carry the RFLP mutation as well. If the RFLP mutation occurred
many generations before that causing the disease then the RFLP
mutation will be found in a proportion of unaffected individuals.
Therefore, differences in evolutionary timing may reduce the statistical
power of such an analysis, particularly in small sample populations
(Harrap, 1994); however, the high degree of similarity of RFLP allele,
genotype, and haplotype frequencies between the two groups suggests
that neither the 5α-reductase type I nor the 5α-reductase type II genes
play a major role in MPB.
Linkage analyses provide other means of testing genetic hypotheses;
however, MPB presents special problems in this regard. The analysis
of multigenerational pedigrees is confounded by the possibility of
asymptomatic female carriers. One alternative is affected relative pair
analysis (Risch, 1990). Although bald father–son pairs are relatively
frequent, they are not informative in linkage analysis. Affected siblings
are another analytical strategy (Kruglyak and Lander, 1995); however,
when selection is limited to young bald brothers, statistical power is
limited by relatively small numbers. In this study based on 828 families
comprising 3000 subjects, only 14 affected brothers were identified. A
study by Carey et al (1993) postulated that polycystic ovary syndrome
may be the female phenotype of premature MPB. If this is shown to
be correct, female carriers of the disorder may then be more easily
recognized, facilitating linkage analyses.
MPB is usually described in the literature as being inherited in an
autosomal dominant fashion, and both 5α-reductase genes are located
on autosomes. This opinion regarding inheritance arose from a study
by Osborn (1916) in which, based on data from 22 families, it was
suggested that MPB was autosomal dominant in men, and autosomal
recessive in women. This hypothesis has not been tested thoroughly
and, as reviewed by Kuster and Happle (1984), considerable doubt
exists. In their analysis of five previous studies, Kuster and Happle
concluded that a polygenic mode of inheritance was more likely.
The family patterns of MPB seen in our study also did not appear
to resemble those of an autosomal dominant trait. Under the assumption
of autosomal dominance, one would expect that bald sons would
inherit the condition from either the mother or the father in equal
proportion. We found that 32 (i.e., 59.3%) of 54 bald sons had fathers
with a greater degree of baldness. This would be consistent with a
dominant trait; however, if we consider any significant baldness as
indicative of genetic predisposition, then 44 bald sons (i.e., 81.5%) had
bald fathers. This considerably exceeds the expected concordance
between fathers and sons under an autosomal dominant model.
Furthermore, when considering the sons of fathers with no significant
baldness, only one was significantly bald. Overall, we observed cosmet-
ically significant baldness in 11.1% of sons in the Victorian Family
Heart Study. Therefore, if autosomal dominant we would have expected
that approximately half of this proportion (or about four in our sons
of controls) might have inherited predisposition to baldness from their
mothers. This difference between the expected (assuming autosomal
dominance) and the observed number of bald sons of nonbald fathers
was not significant by chi-square analysis (p 5 0.17); however, the
relatively small group sizes preclude any firm conclusions. Nevertheless,
our observations would not be inconsistent with those of a polygenic
trait.
Given the negative results and the possibility that several genes may
contribute to MPB, other candidates deserve attention. Among these
are genes relevant to the androgen pathway, such as aromatase and
steroid hormone binding globulin. The androgen receptor gene is
localized to the X chromosome (Brown et al, 1989) and therefore
could not explain paternal inheritance.
Other genes outside the direct androgen pathway should also be
considered. Free radicals are thought to modulate hair growth (Proctor,
1989), and minoxidil that acts in a way similar to the endogenous free
radical nitric oxide has been used to increase hair growth (Diani et al,
1992; Walsh et al, 1995). Therefore, the endothelial nitric oxide gene
NOS3 that regulates the production of nitric oxide is a potential
candidate for MPB. Additionally, the insulin gene may also be worthy
of study, given the findings of a recent paper linking this gene with
polycystic ovary syndrome (Waterworth et al, 1997).
In conclusion, although likely physiologic candidates, the 5α-
reductase genes do not appear to be associated with MPB. Other
candidate genes warrant further investigation to define genetic markers
to help elucidate diagnosis, prevention, and possibly treatment of MPB.
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